NEW YORK, March 7, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today provided a corporate update and announced encouraging results of its analysis of secondary endpoints and post hoc analysis from its National Institute of Health ("NIH") - sponsored Phase 2 extended clinical trial evaluating the safety, tolerability, and long-term efficacy of Bryostatin-1 for the treatment of advanced Alzheimer's disease (AD).
Read more at prnewswire.comSynaptogenix Provides Corporate Update and Outlines Potential Business Opportunities
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
/Meta%20by%20creativeneko%20via%20Shutterstock.jpg)
